Patents Assigned to FMC Biopolymer AS
-
Patent number: 7767456Abstract: The present invention concerns a composition comprising complexes of cationic chitosan oligomers derived from the cationic polysaccharide chitosan, wherein said cationic oligomers contain a weight fraction of less than 20% of oligomers with a Degree of Polymerization (DP)<10 in addition to a weight fraction of less than 20% with DP>50, and a nucleic acid. These compositions comprising well-defined cationic chitosan oligomers having a certain distribution of chain lengths, and nucleic acid are advantageous to achieve delivery of the nucleic acid into cells of a selected tissue, and to obtain in vivo expression of the desired molecules encoded for by the nucleic acid.Type: GrantFiled: June 1, 2007Date of Patent: August 3, 2010Assignee: FMC Biopolymer ASInventors: Per Artursson, Bjorn Erik Christensen, Magnus Koping-Hoggard, Kjell Morten Varnum
-
Patent number: 7674837Abstract: Gelled biopolymer based foams are disclosed. The gelled foams comprise a cross-linked biopolymer, preferably alginate; optionally, a foaming agent such as hydroxy propyl methyl cellulose; and a plasticizer, preferably glycerin sorbitol, or a mixture thereof, that forms the predominant portion of the gelled foam. The foams are soft and pliable and have high absorbency. They are used as wound dressing materials, controlled release delivery systems, cell culture, barrier media for preventing tissue adherence, and bioabsorbable implants. They also have various personal care applications, especially in oral hygiene, and can be used in food applications.Type: GrantFiled: September 2, 2004Date of Patent: March 9, 2010Assignee: FMC Biopolymer ASInventors: Olav Gaserod, Peder Oscar Andersen, Rolf Myrvold
-
Patent number: 7671102Abstract: Gelled biopolymer based foams are disclosed. The gelled foams comprise a cross-linked biopolymer, preferably alginate; optionally, a foaming agent such as hydroxy propyl methyl cellulose; and a plasticizer, preferably glycerin sorbitol, or a mixture thereof, that forms the predominant portion of the gelled foam. The foams are soft and pliable and have high absorbency. They are used as wound dressing materials, controlled release delivery systems, cell culture, barrier media for preventing tissue adherence, and bioabsorbable implants. They also have various personal care applications, especially in oral hygiene, and can be used in food applications.Type: GrantFiled: November 15, 2006Date of Patent: March 2, 2010Assignee: FMC Biopolymer ASInventors: Olav Gaserod, Peder Oscar Andersen, Rolf Myrvold
-
Patent number: 7671100Abstract: Gelled biopolymer based foams are disclosed. The gelled foams comprise a cross-linked biopolymer, preferably alginate; optionally, a foaming agent such as hydroxy propyl methyl cellulose; and a plasticizer, preferably glycerin sorbitol, or a mixture thereof, that forms the predominant portion of the gelled foam. The foams are soft and pliable and have high absorbency. They are used as wound dressing materials, controlled release delivery systems, cell culture, barrier media for preventing tissue adherence, and bioabsorbable implants. They also have various personal care applications, especially in oral hygiene, and can be used in food applications.Type: GrantFiled: November 3, 2006Date of Patent: March 2, 2010Assignee: FMC Biopolymer ASInventors: Olav Gaserod, Peder Oscar Andersen, Rolf Myrvold
-
Patent number: 7671101Abstract: Gelled biopolymer based foams are disclosed. The gelled foams comprise a cross-linked biopolymer, preferably alginate; optionally, a foaming agent such as hydroxy propyl methyl cellulose; and a plasticizer, preferably glycerin sorbitol, or a mixture thereof, that forms the predominant portion of the gelled foam. The foams are soft and pliable and have high absorbency. They are used as wound dressing materials, controlled release delivery systems, cell culture, barrier media for preventing tissue adherence, and bioabsorbable implants. They also have various personal care applications, especially in oral hygiene, and can be used in food applications.Type: GrantFiled: November 3, 2006Date of Patent: March 2, 2010Assignee: FMC Biopolymer ASInventors: Olav Gaserod, Peder Oscar Andersen, Rolf Myrvold
-
Publication number: 20090226977Abstract: It is described biologically pure bacterial cultures of mutant strains of Pseudomonas fluorescens, which produces large amounts of alginate. The alginate may contain a certain determined content of mannuronate and guluronate residues, possible presence and determined level of acetyl groups in the alginate, and a desired molecular weight of the alginate. Also high yielding mutants with regulation of alginate production, is described. The invention further provides methods for producing new mutant strains of Pseudomonas fluorescens and variants thereof, and use of the resulting strains in alginate production.Type: ApplicationFiled: May 19, 2009Publication date: September 10, 2009Applicant: FMC Biopolymer ASInventors: Martin Gimmestad, Havard Sletta, Karuna Ponniah Karunakaran, Karianne Bakkevig, Helga Ertesvag, Trond Ellingsen, Gudmund Skjak-Braek, Svein Valla
-
Patent number: 7553656Abstract: It is described biologically pure bacterial cultures of mutant strains of Pseudomonas fluorescens, which produces large amounts of alginate. The alginate may contain a certain determined content of mannuronate and guluronate residues, possible presence and determined level of acetyl groups in the alginate, and a desired molecular weight of the alginate. Also high yielding mutants with regulation of alginate production, is described. The invention further provides methods for producing new mutant strains of Pseudomonas fluorescens and variants thereof, and use the resulting strains in alginate production.Type: GrantFiled: July 24, 2003Date of Patent: June 30, 2009Assignee: FMC Biopolymer ASInventors: Martin Gimmestad, Havard Sletta, Karuna Ponniah Karunakaran, Karianne Bakkevig, Helga Ertesvag, Trond Ellingsen, Gudmund Skjak-Braek, Svein Valla
-
Publication number: 20090123596Abstract: A gastro-activated dietary fiber comprising an insoluble polysaccharide salt and use of the gastro-activated dietary fiber in ingestible products. The gastro-activated dietary fibers may include salts of biopolymers such as alginates, carrageenans and pectins that are insoluble in water and exhibit minimal or no swelling in water. The water swelling ratio of the gastro-activated dietary fiber may 15 or less. The gastro-activation of the dietary fiber may be induced by exposure to an acidic pH of 3 or less for at least 15 minutes. Ingestible compositions containing the gastro-activated dietary fiber solubilize and provide a viscosity increase in the digestive tract as a result of activation of the dietary fiber by natural excretions of the small intestine which induce gelation of the dietary fiber.Type: ApplicationFiled: June 18, 2007Publication date: May 14, 2009Applicant: FMC Biopolymer ASInventor: Olav Gaserod
-
Publication number: 20080199914Abstract: Process for preparing a modified alginate polymers are disclosed. The processes comprise the steps of covalently attaching a modifying moiety to one or more unmodified monomeric subunits of an alginate polymer; and changing one or more unmodified mannuronic (M) monomeric subunits of the alginate polymer to one or more unmodified guluronic (G) monomeric sub-units by an enzymatic epimerization reaction performed in any order. Processes for preparing alginate gels, fiber, and compositions are also disclosed. Modified alginates in which only M monomeric subunits are modified, and alginate gels, fibers and compositions comprising the same, are disclosed.Type: ApplicationFiled: November 11, 2005Publication date: August 21, 2008Applicant: FMC BIOPOLYMER ASInventors: Gudmund Skjak-Braek, Ivan Donati
-
Publication number: 20080138416Abstract: Compositions comprising biopolymers such as alginates and cell attachment peptides are disclosed. Compositions may optionally further comprise cells. Methods for repairing or treating a tissues and organs with such compositions and systems for providing such compositions to tissues and organs, and methods for delivering desired proteins to individual with such compositions and systems for providing such compositions are also disclosed. In vitro methods of culturing cells are also disclosed.Type: ApplicationFiled: June 13, 2007Publication date: June 12, 2008Applicant: FMC BIOPOLYMER ASInventors: Francis Rauh, Randall J. Lee, Mark Maciejewski
-
Publication number: 20080131371Abstract: Low molecular weight low molecular weight chitosan oligomers were able to self-assemble siRNA into nanosized particles, provide protection against enzymatic degradation, and mediate gene silencing that is stable over a long period of time in vitro. The control of structural variables in formulating complexes of siRNA with low molecular weight chitosans provides an efficient alternative delivery system for siRNA in vitro and in vivo.Type: ApplicationFiled: September 14, 2007Publication date: June 5, 2008Applicant: FMC BIOPOLYMER ASInventors: Per Artur Sven Artursson, Mohamed Mahmoud Issa, Sabina Prochazkova Strand, Kjell Morten Varum
-
Publication number: 20080085295Abstract: The present invention is directed to a hydrogel comprising an alginate having a low molecular weight (e.g., less than 75,000 Daltons), wherein the alginate is present in a high concentration (e.g., greater than 2.5% by weight of the hydrogel). The present invention is also directed to methods of making and using the hydrogel, as well as products containing the hydrogel.Type: ApplicationFiled: June 13, 2007Publication date: April 10, 2008Applicant: FMC BIOPOLYMER ASInventors: Jan Melvik, Olav Gaserod
-
Publication number: 20080050417Abstract: The present invention is directed to cellular devices comprising a collagen matrix, cell layer, and gelled alginate layer, processes for producing the devices, methods of implanting the devices, and methods of treatment thereof.Type: ApplicationFiled: June 13, 2007Publication date: February 28, 2008Applicant: FMC BIOPOLYMER ASInventors: Denis Dufrane, Pierre Gianello, Jan Melvik
-
Publication number: 20070298048Abstract: The present invention concerns a composition comprising complexes of cationic chitosan oligomers derived from the cationic polysaccharide chitosan, wherein said cationic oligomers contain a weight fraction of less than 20% of oligomers with a Degree of Polymerization (DP)<10 in addition to a weight fraction of less than 20% with DP>50, and a nucleic acid. These compositions comprising well-defined cationic chitosan oligomers having a certain distribution of chain lengths, and nucleic acid are advantageous to achieve delivery of the nucleic acid into cells of a selected tissue, and to obtain in vivo expression of the desired molecules encoded for by the nucleic acid.Type: ApplicationFiled: June 1, 2007Publication date: December 27, 2007Applicant: FMC Biopolymer ASInventors: Per Artursson, Bjorn Christensen, Magnus Koping-Hoggard, Kjell Varum
-
Publication number: 20070087038Abstract: A method for the administration of a composition that augments the acidity of gastric fluid such that intra-gastric gelation of the polysaccharide:acid soluble multivalent cation formulation is initiated independent of endogenous acid secretion. The composition includes:(a) at least one of a polysaccharide, modified polysaccharide, or polysaccharide salt, each capable of ionotropic gelation, (b) at least one source of multivalent cations capable of solubilization at an acidic pH, and (c) at least one acid component capable of providing a controlled release of protons sufficient to solubilize the multivalent cations. The composition is capable of hydrating in aqueous media and subsequently forming a gel in a stomach when ingested, which gel resists peristaltic forces and remains in the stomach for an extended time.Type: ApplicationFiled: October 4, 2006Publication date: April 19, 2007Applicant: FMC BIOPOLYMER ASInventors: JOHNATHAN RICHARDSON, PETER DETTMAR, OLAV GASEROD, TROND HELGERUD
-
Patent number: 6926888Abstract: Encapsulated producer cells which are capable of expressing a molecule which is an inhibitor of CNS tumour growth provide a novel approach to the treatment of tumours, such as brain tumors which are localized within the central nervous system.Type: GrantFiled: August 25, 1999Date of Patent: August 9, 2005Assignee: FMC Biopolymer ASInventor: Rolf Bjerkvig
-
Publication number: 20050170355Abstract: The present invention concerns a composition comprising complexes of cationic chitosan oligomers derived from the cationic polysaccharide chitosan, wherein said cationic oligomers contain a weight fraction of less than 20% of oligomers with a Degree of Polymerization (DP)<10 in addition to a weight fraction of less than 20% with DP>50, and a nucleic acid. These compositions comprising well-defined cationic chitosan oligomers having a certain distribution of chain lengths, and nucleic acid are advantageous to achieve delivery of the nucleic acid into cells of a selected tissue, and to obtain in vivo expression of the desired molecules encoded for by the nucleic acid.Type: ApplicationFiled: May 2, 2003Publication date: August 4, 2005Applicant: FMC Biopolymer ASInventors: Per Artursson, Bjorn Christensen, Magnus Koping-Hoggard, Kjell Varum
-
Publication number: 20050164964Abstract: The present invention concerns a novel composition comprising a nucleic acid; and a chitosan containing branching groups covalently linked to the amino groups wherein said branches are selected from the following groups; alkyl with 2 or more carbon atoms, monosaccharides, oligosaccharides or polysaccharides. The composition is particularly useful as a non-viral gene delivery system. The composition facilitates the introduction of the nucleic acid into the cells to which it is administrated, as well as the expression of the function of the nucleic acid.Type: ApplicationFiled: May 2, 2003Publication date: July 28, 2005Applicant: FMC Biopolymer ASInventors: Per Artursson, Bjorn Christensen, Magnus Koping-Hoggard, Kjell Varum, Kristoffer Tommeraas
-
Publication number: 20050106233Abstract: The present invention is directed to seamless capsules and methods for making seamless capsules having a high oil content. More specifically, the present invention is directed to seamless capsules, and methods for making seamless capsules, made from a process involving the steps of: (a) preparing an emulsion comprising oil, water, an emulsifier, and at least one of a water-soluble monovalent metal salt, polyvalent metal salt, and an acid, wherein said oil is present in an amount of at least 50% by weight of said emulsion; with the proviso that said emulsion does not contain marmelo mucilage; and (b) adding portions of said emulsion to an aqueous gelling bath comprised of at least one ionic polysaccharide, thereby encapsulating said portions of said emulsion in a polysaccharide gel membrane, and optionally (c) drying the resulting capsules by removing water. The capsule is, for example, an alignate gel. The capsules of the invention are suitable for a variety of applications, e.g.Type: ApplicationFiled: April 4, 2003Publication date: May 19, 2005Applicant: FMC Biopolymers ASInventors: Peder Andersen, Olav Gaserod, Christian Larsen
-
Patent number: 6407226Abstract: The use of G-block polysaccharides as a modulator for the rheology in a mixture in which a gelling, water-soluble polysaccharide is a component to give the final product a changed viscosity, stability, elasticity, rigidity or similar.Type: GrantFiled: July 11, 1997Date of Patent: June 18, 2002Assignee: FMC Biopolymer ASInventors: Merethe Kamfjord Simensen, Edvar Onsøyen, Kurt Ingar Draget, Olav Smidsrød, Therese Fjæreide